| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.9 - Pollen Allergy | 2014 | Czech Republic | IgE | 826 | 9.400 | 20140606, Panzner P
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Austria | IgE | 217 | 22.000 | 20141002, Deifl S
| | 1.11 - Esophagitis, Diagnosed | 2014 | Spain | IgE | 67 | 7.400 | 20140625, Armentia A
| | 1.1 - Asymptomatic | 2014 | Spain | IgE | 50 | 0.000 | 20140625, Armentia A
| | 1.9 - Pollen Allergy | 2014 | Spain | IgE | 50 | 4.000 | 20140625, Armentia A
| | 1.12 - Oral Allergy Syndrome | 2014 | Belgium | IgE | 38 | 18.420 | 20140718, Faber MA
| | 1.6 - Anaphylaxis, Diagnosed | 2014 | Belgium | IgE | 37 | 5.400 | 20140718, Faber MA
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 37 | 14.000 | 20140127, Konradsen JR
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 28 | 7.000 | 20140127, Konradsen JR
| | 1.1 - Asymptomatic | 2014 | Belgium | IgE | 15 | 26.670 | 20140718, Faber MA
| | 10.1 - Normal Control | 2014 | Belgium | IgE | 15 | 0.000 | 20140718, Faber MA
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Belgium | IgE | 14 | 0.000 | 20140718, Faber MA
| | 1.5 - Atopic Dermatitis, Diagnosed | 2013 | Germany | IgE | 140 | 5.710 | 20130111, Ott H
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2013 | Netherlands | IgE | 82 | 18.290 | 20130415, Masthoff LJ
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2013 | Netherlands | IgE | 79 | 10.130 | 20130415, Masthoff LJ
| | 1.11 - Esophagitis, Diagnosed | 2013 | Netherlands | IgE | 76 | 7.800 | 20131020, van Rhijn BD
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2013 | China | IgE | 49 | 36.700 | 20130624, Ma S
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2013 | China | IgE | 38 | 34.200 | 20130624, Ma S
| | 1.11 - Esophagitis, Diagnosed | 2013 | Switzerland | IgE | 35 | 37.140 | 20130605, Simon D
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2013 | Thailand | IgE | 21 | 4.800 | 20131011, Suratannon N
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2013 | Thailand | IgE | 19 | 15.800 | 20131011, Suratannon N
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2013 | China | IgE | 16 | 31.250 | 20130510, Ma S
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 0.810 | 20120528, Patelis A
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 16.160 | 20110223, De Knop KJ
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 4.170 | 20120528, Patelis A
| | 4.1.8 - Heterologous Source Sensitized (SPT, IgE) | 2012 | Spain | IgE | 68 | 19.100 | 20120726, Pedrosa M
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2012 | Spain | IgE | 55 | 14.500 | 20120726, Pedrosa M
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Denmark | IgE | 30 | 10.000 | 20120410, Ballmer-Weber BK
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Switzerland | IgE | 21 | 29.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Denmark | IgE | 20 | 15.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Spain | IgE | 20 | 15.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Switzerland | IgE | 20 | 35.000 | 20120410, Ballmer-Weber BK
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Spain | IgE | 9 | 67.000 | 20120410, Ballmer-Weber BK
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2011 | Italy | IgE | 148 | 38.510 | 20110810, Pastorello EA
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2011 | Austria | IgE | 147 | 14.970 | 20110121, Geroldinger-Simic M
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2011 | Sweden | IgE | 74 | 17.570 | 20110701, Moverare R
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2011 | Italy | IgE | 43 | 97.670 | 20110214, Villalta D
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 6.010 | 20100301, Scala E
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | Czech Republic | IgE | 178 | 21.300 | 20101026, Sekerkova A
| | 3.2.1 - Source Sensitized (IgE) | 2010 | Sweden | IgE | 100 | 7.000 | 20100212, Asarnoj A
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 16.270 | 20101214, Gadisseur R
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2010 | Sweden | IgE | 50 | 0.000 | 20100212, Asarnoj A
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2010 | China | IgE | 44 | 13.630 | 20101229, Han D
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2010 | China | IgE | 17 | 23.530 | 20101229, Han D
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2010 | China | IgE | 13 | 30.770 | 20101229, Han D
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Austria | IgE | 54 | 48.150 | 20090416, Gaier S
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 16.210 | 20090826, Ebo DG
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Switzerland | IgE | 24 | 25.000 | 20091005, Bauermeister K
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 4.550 | 20091121, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Italy | IgE | 21 | 0.000 | 20090808, Krause S
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 75.000 | 20091121, Ebo DG
| | 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 10.000 | 20091005, Ott H
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2009 | Switzerland | IgE | 20 | 15.000 | 20091005, Bauermeister K
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Spain | IgE | 17 | 82.350 | 20091215, Tordesillas L
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Italy | IgE | 7 | 100.000 | 20091030, Quercia O
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2008 | Italy | IgE | 246 | 30.000 | 20080613, Wopfner N
| | 3.2.1 - Source Sensitized (IgE) | 2008 | Japan | IgE | 55 | 27.300 | 20080319, Morita A
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2008 | Germany | IgE | 50 | 14.000 | 20081129, Treudler R
| | 3.2.1 - Source Sensitized (IgE) | 2005 | Finland | IgE | 55 | 13.000 | 20041224, Moverare R
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2005 | Switzerland | IgE | 39 | 33.300 | 20050714, Ballmer-Weber BK
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2005 | Germany | HRT | 32 | 25.000 | 20050218, Erdmann SM
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2005 | Germany | IgE | 32 | 15.600 | 20050218, Erdmann SM
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2005 | Switzerland | IgE | 21 | 33.300 | 20050714, Ballmer-Weber BK
| | 3.2.1 - Source Sensitized (IgE) | 2005 | Russian Federation | IgE | 5 | 20.000 | 20041224, Moverare R
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2004 | Belgium | IgE | 24 | 20.800 | 20040116, Ebo D
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2004 | Switzerland | IgE | 22 | 22.700 | 20040416, Westphal S
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2004 | Netherlands / Switzerland | IgE | 20 | 35.000 | 20041204, Mittag D
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2004 | Poland | IgE | 14 | 21.000 | 20050112, Cudowska B
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2004 | Germany / Spain | IgE (IB) | 11 | 100.000 | 20040416, Westphal S
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2003 | Italy | IgE | 372 | 44.600 | 20030814, Rossi RE
| | 3.1.1 - Source Sensitized (SPT) | 2003 | Italy | IgE | 370 | 47.600 | 20031005, Mari A
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2003 | Italy | IgE | 80 | 30.300 | 20030816, Asero R
| | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2003 | Spain | IgE | 76 | 32.900 | 20031017, Fernandez-Rivas M
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 2003 | Switzerland | IgE | 34 | 26.500 | 20030814, Tresch S
| | 4.1.3 - Heterologous Source Sensitized (SPT) | 2003 | Spain | IgE (IB) | 29 | 51.700 | 20030629, Rodriguez-Perez R
| | 3.2.1 - Source Sensitized (IgE) | 2003 | Austria | IgE | 10 | 10.000 | 2003a, Westritschnig K
| | 3.2.1 - Source Sensitized (IgE) | 2003 | Zimbabwe | IgE | 3 | 100.000 | 2003a, Westritschnig K
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | France | IgE | 51 | 20.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Austria | IgE | 50 | 30.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Sweden | IgE | 42 | 12.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Finland | IgE | 41 | 2.000 | 2002a, Moverare R
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Switzerland | IgE | 37 | 43.000 | 2002a, Moverare R
| | 3.1.1 - Source Sensitized (SPT) | 2002 | France | IgE | 32 | 37.500 | 2002a, Moverare R
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2002 | Denmark | IgE | 24 | 8.300 | 2002, Luttkopf D
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2002 | Italy | IgE | 21 | 33.000 | 2002a, Moverare R
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2002 | Germany | IgE (IB) | 19 | 42.100 | 2002, Reindl J
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2002 | Switzerland | IgE | 19 | 26.300 | 2002, Luttkopf D
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2002 | Germany | IgE (IB) | 16 | 43.700 | 2002, Reindl J
| | 4.1.3 - Heterologous Source Sensitized (SPT) | 2001 | Italy | IgE | 177 | 55.000 | 2001, Mari A
| | 4.1.8 - Heterologous Source Sensitized (SPT, IgE) | 2001 | Italy | IgE | 77 | 33.800 | | | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2001 | Germany | IgE | 32 | 53.100 | | | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2001 | Switzerland | IgE | 20 | 40.000 | 2001, Ballmer-Weber BK
| | 5.3.2 - Source Exposed (Symptoms, high IgE) | 2001 | Germany | IgE | 8 | 25.000 | | | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2000 | Germany | IgE | 42 | 16.700 | | | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 2000 | Switzerland | IgE | 22 | 27.300 | | | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2000 | Switzerland | IgE | 22 | 27.300 | | | 3.2.1 - Source Sensitized (IgE) | 1999 | Netherlands | IgE | 223 | 63.700 | 1999, Van Ree R
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 1999 | Germany | IgE | 15 | 73.300 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1998 | Austria | IgE | 38 | 18.400 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1998 | Austria | SPT | 20 | 35.000 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1998 | Switzerland | IgE | 18 | 5.500 | | | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 1996 | Italy | IgE | 65 | 56.900 | 1996, Rossi RE
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | France | IgE | 51 | 19.600 | 1996, Pauli G
| | 5.4.2 - Source Exposed (Symptoms, SPT, high IgE) | 1996 | Switzerland | IgE (IB) | 51 | 19.600 | 1996, Menz G
| | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 1996 | France | IgE | 38 | 8.000 | | | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 1996 | Sweden | IgE | 35 | 11.000 | | | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 1996 | Austria | IgE | 29 | 14.000 | | | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 1996 | Denmark | IgE | 26 | 12.000 | | | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 1996 | Japan | IgE | 20 | 5.000 | | | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 1996 | Switzerland | IgE | 20 | 15.000 | | | 4.1.2 - Heterologous Source Sensitized (Symptoms, SPT) | 1996 | Canada | IgE | 15 | 13.000 | |
|
Loading...
Bet v 2
